The pharmaceutical sector has been dogged by decades of excesses which have diminished the need for strategy.
The pharmaceutical sector has been dogged by decades of excesses which have diminished the need for strategy. We have been operating in special environments and the industry has taken full advantage of insulation from market realities. The insulation is being removed slowly - and rightfully so. It is time that our sector is ran with similar efficiencies that other verticals operate with. These changes though subtle will mean the need for strong competitive strategies will increase. It is right of consumers and Goverments to ask questions of the industry, the fact we create value does not mean the cost of the value we create cannot be questioned. The successful Pharmaceutical companies of the next decades will be a totally different animal to today's organisations.
blog comments powered by DisqusKevin Appareti, global director for Medical Science Liaison at Philips Healthcare, explains how to motivate KOLs and how to measure their value
The Mobile Health Competition is now closed, but the journey is just beginning for the winning idea.
Phil Taylor reports on the commercial and scientific opportunities facing medical scientific liaisons (MSLs)
Alex Gochtovtt, principal with Cognizant’s enterprise analytics practice, discusses pharma’s social media opportunities and the importance of data analytics
An interview with Serkan Erkovan of Boehringer Ingelheim.
Ashok Bhaseen, Vice President of Sales & Marketing at Pediapharm reveals how his company establishes trust when engaging KOLs